Press Releases

Jul 19, 2023

Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023

Read More

Jun 20, 2023

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Read More

Jun 12, 2023

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

Read More

May 25, 2023

New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer

Read More

May 24, 2023

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Read More

May 23, 2023

Veracyte to Participate in Upcoming Investor Conferences

Read More

May 12, 2023

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Read More

May 04, 2023

Veracyte Announces First Quarter 2023 Financial Results

Read More

May 04, 2023

New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules

Read More

May 03, 2023

New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients

Read More